Amgen, Inc. (AMGN) Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP trimmed its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,383 shares of the medical research company’s stock after selling 623 shares during the period. GSA Capital Partners LLP’s holdings in Amgen were worth $1,738,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its position in shares of Amgen by 10.4% during the second quarter. Alps Advisors Inc. now owns 5,525 shares of the medical research company’s stock valued at $961,000 after buying an additional 519 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Amgen by 641.8% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,040 shares of the medical research company’s stock valued at $377,000 after buying an additional 1,765 shares during the period. Dana Investment Advisors Inc. increased its position in shares of Amgen by 6.0% during the second quarter. Dana Investment Advisors Inc. now owns 150,404 shares of the medical research company’s stock valued at $27,763,000 after buying an additional 8,452 shares during the period. Synovus Financial Corp increased its position in shares of Amgen by 2.5% during the second quarter. Synovus Financial Corp now owns 55,967 shares of the medical research company’s stock valued at $10,325,000 after buying an additional 1,341 shares during the period. Finally, First Midwest Bank Trust Division increased its position in shares of Amgen by 10.4% during the second quarter. First Midwest Bank Trust Division now owns 15,092 shares of the medical research company’s stock valued at $2,785,000 after buying an additional 1,427 shares during the period. Institutional investors and hedge funds own 76.94% of the company’s stock.
In other Amgen news, SVP Cynthia M. Patton sold 1,777 shares of the stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $202.88, for a total transaction of $360,517.76. Following the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.19% of the stock is owned by company insiders.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The business had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. During the same period last year, the business earned $3.27 earnings per share. The business’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that Amgen, Inc. will post 14.24 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date is Thursday, November 15th. Amgen’s payout ratio is currently 41.97%.
Several brokerages have recently weighed in on AMGN. Oppenheimer reiterated a “buy” rating and set a $224.00 price target on shares of Amgen in a research report on Tuesday, October 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $220.00 price target on shares of Amgen in a research report on Friday, August 24th. Morgan Stanley upped their price target on Amgen from $210.00 to $212.00 and gave the company an “overweight” rating in a research report on Thursday, October 11th. Leerink Swann set a $209.00 price objective on shares of Amgen and gave the stock a “hold” rating in a research report on Monday, September 17th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $223.00 price objective on shares of Amgen in a research report on Tuesday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $205.68.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.